Mikhail Blagosklonny: Championing for Greater Understanding of Oncology

One of the greatest challenges in the fight against cancer is the inadequacy of crucial information that is pertinent in developing more effective treatment and management options. However, over the years scientists such as Mikhail Blagosklonny have made great progress in demystifying the scourge that has become one of the leading causes of death globally in a few short years. The professor at Roswell Park Cancer Institute who specializes in oncology is also a research scientist with several scientific publications touching on oncology and aging to his name. With more studies indicating that the manifestation of aging has some commonalities with that of cancer, the First Pavlov State Medical University of St. Petersburg trained oncologist believes that understanding the signaling pathways for aging especially Target of Rapamycin (TOR) has the potential of finding the treatment for more than just aging. It has the potential of treating of cardiovascular diseases, cancer and Parkinson’s disease among others.

Drawing from his years of scholarly experience working as a research scientist, professor across several institutions including New York Medical College, Mikhail Blagosklonny believes that conceptualizing the TOR signaling pathway can create a model that build upon previous studies into its potential. His hypothesis postulates that the popular cancer drug has the anti-aging qualities and hence can be used to extend the human lifespan. This is because it eliminates the hyper-immunity of the body that is responsible for aging of cells. He also holds that TOR-centric model is hinged on inactivation of genes responsible for extending lifespan, increasing cell senescence and eliminating age-related diseases. With lifespan extended, Mikhail Blagosklonny believes that new causes of death will emerge over time.

Scholarly and professional Dedication to Understanding Oncology

Mikhail Blagosklonny has unrivalled grasp of oncology and its related conditions such as aging. He is a renowned scholar in the field with two degrees. He specialized in internal medicine for Doctor of Medicine studies. For his Doctor of Philosophy studies, he specialized in cardiology and experimental medicine. He is strongly convicted that, with time, scientists will find a cure for both cancer and aging. He believes that Rapamycin, which is currently being used for this purpose, holds a greater potential of tackling these conditions. This is most of his researches have focused on cell-related topics including anticancer therapeutic, mitosis, tumor suppressors and signal transduction. His professional career, which has also seen him work as a research scientist at Ordway Research Institute, has also seen him research on apoptosis, mechanisms of aging, cell cycle and ontogenesis. Mikhail Blagosklonny is a reputable authority on the topic of oncology. This is why has dedicated his scholarly and professional life to researching and disseminating information on cancer. Towards this end, he cofounded the open access online medical journal, Oncotarget, which is published weekly in English. He also serves as the coeditor-in-chief for the multiple peer-reviewed journal and several others including Cell Cycle and Aging. Additionally, he lends his vast experience in oncology for several other journals as a member of the editorial board. This includes Cell Death & Differentiation and Cancer Biology & Therapy.

Fundamental Truths Concerning Seattle Genetics’ Co-Founder, Clay Siegall

Clay B. Siegall is a Ph.D. holder and a time-proven scientist. His involvement revolves around research, where he focuses on cancer therapies. Clay earned his B.S in Zoology from the University of Maryland and again pursued his Ph.D. from George Washington University. He is committed to finding a lasting solution for the cancer patients and their loved ones. His career life begun taking shape when he worked with National Cancer Institute, National Institutes of Health, between 1988 and 1991. Again in 1991, he started working with the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Dr. Siegall appreciates the invaluable skills he gained in those institutions that he served before co-founding Seattle Genetics.

 

General Information About Seattle Genetics

 

Siegall co-founded Seattle in 1998, and he serves there as the president, CEO and board chairman. The primary reason for the inception was to enhance cancer therapies. There was a great motivation that came from Clay’s father’s illness. Siegall’s father was diagnosed with cancer when he was 19. He suffered from the life-threatening disease for five years, and Clay was watching. Mr. Clay Siegall got motivated to pursue cancer treatment so as to deliver the patients from the agony. The company has registered great milestones so far. They have succeeded in creating drugs that are FDA approved, the major one being in 2011, where their first ADC products were approved.

 

Various Administrative Positions Held by Clay Siegall

 

Mr. Clay served at Onyx Pharmaceuticals, Inc. as the Vice President and Chief Financial Officer. As well, he served as an independent director for Ultragenyx. The pharmaceuticals firm took him in because they believed in his proven proficiency in the biopharmaceutical industry. When joining the company, Clay appreciated the significant progress they had made in their clinical programs. Being a supporter of development, he pledged his allegiance in working with Ultragenyx in achieving greater goals ahead of them.

 

Clay’s Appointment at Mirna Therapeutics Inc.

 

In January 2013, Clay experienced a boost in his career when he got appointed to the board of directors at Mirna Therapeutics Inc. The firm mainly focuses on creation and commercialization of microRNA (miRNA) therapeutics. Being an exciting environment for cancer research, it got him serving in his most relevant area of specialty.